---
title: "Immuron Stock Surges Friday: What's Driving the Action?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298044643.md"
description: "Immuron (NASDAQ: IMRN) shares surged over 57% in premarket trading on Friday following an exclusive distribution agreement with Calmino group AB to launch the PROIBS gut health product in the U.S. The deal targets the $4.16 billion American digestive health market, expanding Immuron's commercial footprint beyond its Australian launch. PROIBS, a European-certified medical device for abdominal issues, showed high user satisfaction in trials. Management cited this as a key opportunity to grow their digestive health portfolio."
datetime: "2026-09-04T13:11:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298044643.md)
  - [en](https://longbridge.com/en/news/298044643.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298044643.md)
generator: "portal-rs"
---

# Immuron Stock Surges Friday: What's Driving the Action?

Shares of **Immuron Limited** (NASDAQ:IMRN) are surging Friday morning following news that the Australian biopharmaceutical company signed an exclusive agreement to launch PROIBS gut health product in the United States. Here’s what investors need to know.

-   Immuron stock is surging to new heights today. What’s driving IMRN stock higher?

## **Exclusive Partnership Targets $4.16 Billion U.S. Gut Health Market**

According to a Friday announcement, Immuron executed an exclusive distribution agreement with Sweden-based **Calmino** group AB. The deal expands on Immuron’s initial launch of PROIBS in Australia during fiscal year 2026, targeting a high-demand segment of the $4.16 billion U.S. digestive health supplement market.

PROIBS is a European-certified medical device designed for abdominal pain, bloating and unsettled bowel movements. Its active ingredient, AVH200, is derived from *Aloe barbadensis Mill.* and features gel-forming components that support the intestinal mucosal barrier. 

Per the company, in a usability study of 1,003 participants conducted by Calmino, 94% of users reported that PROIBS was helpful, with 91% experiencing improvements in daily life and 98% stating they would recommend the product.

## **Management Commentary Points to Expanding U.S. Commercial Footprint**

**Flavio Palumbo**, Chief Commercial Officer of Immuron, highlighted the expansion: “Following the rapid growth of Travelan sales in the US, we have developed a commercial growth strategy to bring a portfolio of innovative digestive health products to market. PROIBS is a great opportunity to further expand our digestive health portfolio by providing our customers with a proven premium product that delivers improvement in daily life.”

**Tobias Kisker**, CEO and founder of Calmino group AB, added: “We are immensely proud to further expand our collaboration with Immuron. What started with PROIBS in Australia is now developing into a partnership across two continents, with the United States becoming our next important market together.”

## IMRN Stock Skyrockets Friday Morning

**IMRN Price Action:** Immuron shares were up 57.66% at $1.75 during premarket trading on Friday, according to Benzinga Pro data.

 **Read Also: What's Going On With DocuSign Stock Friday?** 

*Image: Shutterstock*

### Related Stocks

- [IMRN.US](https://longbridge.com/en/quote/IMRN.US.md)
- [IMC.AU](https://longbridge.com/en/quote/IMC.AU.md)
- [DOCU.US](https://longbridge.com/en/quote/DOCU.US.md)

## Related News & Research

- [Immuron To Launch PROIBS In U.S. After Australia Debut; Pre-market Shares Up](https://longbridge.com/en/news/298028882.md)
- [Immuron to launch PROIBS® in the United States | IMRN Stock News](https://longbridge.com/en/news/298022732.md)
- [Immuron FY26 net sales rise 6% to AUD 7.7 million](https://longbridge.com/en/news/297303231.md)
- [TEVA: TEV ‘408 significantly prevented gluten-induced intestinal damage in celiac disease Phase 2a study](https://longbridge.com/en/news/297776333.md)
- [Teva Reports Significant Prevention Of Gluten-Induced Damage in New Study](https://longbridge.com/en/news/297800772.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**